Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Astrazeneca (AZN) Regulatory News

Date Source Headline
26th Feb 2019 7:00 am RNS Lynparza significantly delayed disease progression
25th Feb 2019 7:00 am RNS Brilinta's PhIII THEMIS trial met primary endpoint
14th Feb 2019 7:00 am RNS AstraZeneca Full-Year and Q4 2018 Results
6th Feb 2019 7:00 am RNS US FDA grants Fasenra Orphan Drug Designation
5th Feb 2019 7:05 am RNS US FDA grants Breakthrough Therapy Designation
5th Feb 2019 7:00 am RNS EMA grants PRIME eligibility for MEDI8897
1st Feb 2019 3:00 pm RNS Total Voting Rights
1st Feb 2019 1:17 pm RNS Forxiga receives positive EU CHMP opinion
25th Jan 2019 2:00 pm RNS Completion of divestment of US Synagis rights
7th Jan 2019 1:00 pm RNS AstraZeneca announces organisational changes
2nd Jan 2019 3:00 pm RNS Total Voting Rights
20th Dec 2018 1:47 pm RNS Bevespi Aerosphere approved in the EU for COPD
20th Dec 2018 7:05 am RNS Lynparza meets primary endpoint in SOLO-3 trial
20th Dec 2018 7:00 am RNS Phase III ROCKIES and OLYMPUS roxadustat trials
19th Dec 2018 6:31 pm RNS FDA approves Lynparza as 1L maintenance therapy
18th Dec 2018 9:09 am RNS Roxadustat approved in China for the treatment of
14th Dec 2018 7:00 am RNS Directorate Change
7th Dec 2018 7:00 am RNS Update on the Phase III EAGLE trial of Imfinzi
6th Dec 2018 7:00 am RNS Divestment of rights to Covis completed
4th Dec 2018 3:00 pm RNS Director/PDMR Shareholding
3rd Dec 2018 4:00 pm RNS Block listing Interim Review
3rd Dec 2018 4:00 pm RNS Total Voting Rights
3rd Dec 2018 7:00 am RNS Grünenthal Agreement for Nexium, Vimovo Completed
26th Nov 2018 7:00 am RNS US FDA grants Fasenra ODD for EGPA
16th Nov 2018 7:00 am RNS AstraZeneca provides update on Phase III MYSTIC
13th Nov 2018 7:00 am RNS AstraZeneca to divest US Synagis rights to Sobi
12th Nov 2018 7:05 am RNS US FDA accepts regulatory submission for Lynparza
12th Nov 2018 7:00 am RNS Farxiga significantly reduced hospitalisation for
8th Nov 2018 7:00 am RNS AZN: Year-to-Date and Q3 2018 Results
6th Nov 2018 7:00 am RNS Divestment of rights to Covis Pharma
1st Nov 2018 3:00 pm RNS Total Voting Rights
31st Oct 2018 9:45 am RNS Additional financial information-Grünenthal deal
30th Oct 2018 7:00 am RNS Grünenthal Agreement for rights to Nexium, Vimovo
23rd Oct 2018 7:00 am RNS AstraZeneca Extends Innate Pharma Collaboration
22nd Oct 2018 7:00 am RNS Lynparza shows 70% reduction in PFS ovarian cancer
19th Oct 2018 1:09 pm RNS CHMP positive opinion Bevespi Aerosphere
16th Oct 2018 7:00 am RNS FDA Orphan Drug for Lynparza in pancreatic cancer
1st Oct 2018 3:00 pm RNS Total Voting Rights
1st Oct 2018 7:00 am RNS Atacand Agreement with Cheplapharm Completed
28th Sep 2018 4:00 pm RNS Previous Announcement Regarding Appointment Of NED
FTSE 100 Latest
Value9,162.57
Change34.27